BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 18639281)

  • 1. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor.
    Kim EJ; Kim YJ; Jeong P; Ha YS; Bae SC; Kim WJ
    J Urol; 2008 Sep; 180(3):1141-5. PubMed ID: 18639281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors.
    Kim WJ; Kim EJ; Jeong P; Quan C; Kim J; Li QL; Yang JO; Ito Y; Bae SC
    Cancer Res; 2005 Oct; 65(20):9347-54. PubMed ID: 16230397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
    Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
    J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
    Jiang Y; Tong D; Lou G; Zhang Y; Geng J
    Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RUNX3 methylation and the potential to predict the behavior of bladder cancer.
    Knapp DW
    J Urol; 2008 Sep; 180(3):806-7. PubMed ID: 18635238
    [No Abstract]   [Full Text] [Related]  

  • 6. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased expression of RUNX3 is correlated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma.
    Sugiura H; Ishiguro H; Kuwabara Y; Kimura M; Mitsui A; Mori Y; Ogawa R; Katada T; Harata K; Fujii Y
    Oncol Rep; 2008 Mar; 19(3):713-9. PubMed ID: 18288406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Runt-related transcription factor 3 methylation as a possible prognosticator in muscle-invasive bladder cancer.
    Jeong P; Ha YS; Kim JS; Cho IC; Kim WT; Kim YJ; Yi Kim I; Yun SJ; Lee SC; Cha EJ; Kim WJ
    Cancer Biomark; 2011; 10(5):205-11. PubMed ID: 22699781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RUNX3 methylation in normal surrounding urothelium of patients with non-muscle-invasive bladder cancer: potential role in the prediction of tumor progression.
    Jeong P; Min BD; Ha YS; Song PH; Kim IY; Ryu KH; Kim JH; Yun SJ; Kim WJ
    Eur J Surg Oncol; 2012 Nov; 38(11):1095-100. PubMed ID: 22884471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative assessment of RUNX3 methylation in neoplastic and non-neoplastic gastric epithelia using a DNA microarray.
    So K; Tamura G; Honda T; Homma N; Endoh M; Togawa N; Nishizuka S; Motoyama T
    Pathol Int; 2006 Oct; 56(10):571-5. PubMed ID: 16984612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
    Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
    Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic inactivation of the RUNX3 gene in lung cancer.
    Sato K; Tomizawa Y; Iijima H; Saito R; Ishizuka T; Nakajima T; Mori M
    Oncol Rep; 2006 Jan; 15(1):129-35. PubMed ID: 16328045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter hypermethylation of the RUNX3 gene in esophageal squamous cell carcinoma.
    Long C; Yin B; Lu Q; Zhou X; Hu J; Yang Y; Yu F; Yuan Y
    Cancer Invest; 2007 Dec; 25(8):685-90. PubMed ID: 18058463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma.
    Friedrich MG; Chandrasoma S; Siegmund KD; Weisenberger DJ; Cheng JC; Toma MI; Huland H; Jones PA; Liang G
    Eur J Cancer; 2005 Nov; 41(17):2769-78. PubMed ID: 16242928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
    Subramaniam MM; Chan JY; Soong R; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
    Breast Cancer Res Treat; 2009 Jan; 113(1):113-21. PubMed ID: 18256927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased expression and frequent allelic inactivation of the RUNX3 gene at 1p36 in human hepatocellular carcinoma.
    Mori T; Nomoto S; Koshikawa K; Fujii T; Sakai M; Nishikawa Y; Inoue S; Takeda S; Kaneko T; Nakao A
    Liver Int; 2005 Apr; 25(2):380-8. PubMed ID: 15780064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Promoter methylation and expression of Runx3 gene in gastric cancer].
    Li LY; Li JK; Shen Y; Yu L; Zhang JH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jul; 11(4):379-82. PubMed ID: 18636364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers.
    Sakakura C; Hasegawa K; Miyagawa K; Nakashima S; Yoshikawa T; Kin S; Nakase Y; Yazumi S; Yamagishi H; Okanoue T; Chiba T; Hagiwara A
    Clin Cancer Res; 2005 Sep; 11(18):6479-88. PubMed ID: 16166423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoter hypermethylation identifies progression risk in bladder cancer.
    Yates DR; Rehman I; Abbod MF; Meuth M; Cross SS; Linkens DA; Hamdy FC; Catto JW
    Clin Cancer Res; 2007 Apr; 13(7):2046-53. PubMed ID: 17404085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
    Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.